The  	The  	 DT	O
endogenous  	endogenous  	 JJ	B-NP
cardioprotection  	cardioprotection  	 NN	I-NP
during  	during  	 IN	O
reperfusion  	reperfusion  	 NN	B-NP
in  	in  	 IN	O
acute  	acute  	 JJ	O
myocardial  	myocardial  	 NNS	B-NP
infarction  	infarction  	 VBP	O
A  	A  	 DT	O
prompt  	prompt  	 JJ	O
primary  	primary  	 JJ	B-NP
percutaneous  	percutaneous  	 JJ	I-NP
coronary  	coronary  	 JJ	I-NP
intervention  	intervention  	 NN	I-NP
with  	with  	 IN	O
aspiration  	aspiration  	 JJ	B-NP
thrombectomy  	thrombectomy  	 NN	I-NP
and  	and  	 CC	O
subsequent  	subsequent  	 JJ	O
stent  	stent  	 JJ	B-NP
implantation  	implantation  	 NN	I-NP
at  	at  	 IN	O
the  	the  	 DT	O
culprit  	culprit  	 NN	B-NP
lesion  	lesion  	 VBZ	I-NP
combined  	combined  	 VBN	O
with  	with  	 IN	O
optimal  	optimal  	 JJ	B-NP
anti-platelet  	anti-platelet  	 JJ	I-NP
and  	and  	 CC	O
anti-thrombotic  	anti-thrombotic  	 JJ	B-NP
pharmacotherapy  	pharmacotherapy  	 NN	I-NP
is  	is  	 VBZ	O
the  	the  	 DT	O
safest  	safest  	 NN	O
and  	and  	 CC	O
most  	most  	 RBS	O
effective  	effective  	 JJ	O
reperfusion  	reperfusion  	 JJ	B-NP
strategy 	strategy 	 NN	I-NP
.  	.  	 .	O
Unfortunately 	Unfortunately 	 RB	O
,  	,  	 ,	O
this  	this  	 DT	O
therapy  	therapy  	 NN	O
does  	does  	 VBZ	O
not  	not  	 RB	O
guarantee  	guarantee  	 VB	O
always  	always  	 RB	O
a  	a  	 DT	O
good 	good 	 JJ	O
,  	,  	 ,	O
long-term  	long-term  	 JJ	O
clinical  	clinical  	 JJ	B-NP
outcome  	outcome  	 NN	I-NP
and  	and  	 CC	O
left  	left  	 VBD	O
ventricular  	ventricular  	 JJ	B-NP
function  	function  	 NN	I-NP
recovery 	recovery 	 NN	I-NP
.  	.  	 .	O
Despite  	Despite  	 IN	O
the  	the  	 DT	O
unquestionable  	unquestionable  	 JJ	O
benefit  	benefit  	 NN	O
of  	of  	 IN	O
reperfusion 	reperfusion 	 NN	B-NP
,  	,  	 ,	O
we  	we  	 PRP	O
have  	have  	 VBP	O
evidence  	evidence  	 NN	O
that  	that  	 IN	O
its  	its  	 PRP$	O
initial  	initial  	 JJ	O
phase  	phase  	 NN	O
leads  	leads  	 VBZ	O
to  	to  	 TO	O
additional  	additional  	 JJ	O
damage  	damage  	 NN	O
at  	at  	 IN	O
the  	the  	 DT	O
area  	area  	 NN	O
at  	at  	 IN	O
risk 	risk 	 NN	O
,  	,  	 ,	O
so  	so  	 RB	O
the  	the  	 DT	O
final  	final  	 JJ	B-NP
effect  	effect  	 NN	I-NP
is  	is  	 VBZ	O
the  	the  	 DT	O
compromise  	compromise  	 NN	O
between  	between  	 IN	O
benefits  	benefits  	 NNS	O
and  	and  	 CC	O
destruction 	destruction 	 NN	O
,  	,  	 ,	O
which  	which  	 WDT	O
come  	come  	 VBP	O
with  	with  	 IN	O
the  	the  	 DT	O
reperfusion  	reperfusion  	 JJ	B-NP
wavefront 	wavefront 	 NN	I-NP
.  	.  	 .	O
Experimental  	Experimental  	 JJ	B-NP
studies  	studies  	 NNS	I-NP
suggest  	suggest  	 VBP	O
that  	that  	 DT	O
postconditioning  	postconditioning  	 NN	B-NP
with  	with  	 IN	O
several  	several  	 JJ	O
very  	very  	 RB	O
brief  	brief  	 JJ	O
cycles  	cycles  	 NNS	O
of  	of  	 IN	O
ischaemia  	ischaemia  	 JJ	B-NP
alternating  	alternating  	 NN	I-NP
with  	with  	 IN	O
reperfusion  	reperfusion  	 NN	B-NP
applied  	applied  	 VBD	O
immediately  	immediately  	 RB	O
after  	after  	 IN	O
relief  	relief  	 NN	O
of  	of  	 IN	O
a  	a  	 DT	O
prolonged  	prolonged  	 JJ	O
epicardial  	epicardial  	 JJ	B-NP
occlusion  	occlusion  	 NN	I-NP
is  	is  	 VBZ	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
the  	the  	 DT	O
infarct  	infarct  	 JJ	B-NP
size  	size  	 NN	I-NP
limitation 	limitation 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
cellular  	cellular  	 JJ	B-NP
protective  	protective  	 JJ	I-NP
effect  	effect  	 NN	I-NP
of  	of  	 IN	I-NP
postconditioning  	postconditioning  	 NN	I-NP
seems  	seems  	 VBZ	O
to  	to  	 TO	O
be  	be  	 VB	O
related  	related  	 VBN	O
to  	to  	 TO	O
prevention  	prevention  	 VB	O
of  	of  	 IN	O
mitochondrial  	mitochondrial  	 FW	B-NP
permeability  	permeability  	 FW	I-NP
transition  	transition  	 FW	I-NP
pore  	pore  	 FW	I-NP
activation 	activation 	 FW	I-NP
.  	.  	 .	O
We  	We  	 PRP	O
have  	have  	 VBP	O
still  	still  	 RB	O
to  	to  	 TO	O
wait  	wait  	 VB	O
for  	for  	 IN	O
confirmation  	confirmation  	 NN	B-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
clinical  	clinical  	 JJ	I-NP
effectiveness  	effectiveness  	 NN	I-NP
of  	of  	 IN	O
both  	both  	 DT	O
postconditionig  	postconditionig  	 NN	B-NP
as  	as  	 IN	O
well  	well  	 RB	O
as  	as  	 IN	O
pharmacotherapy  	pharmacotherapy  	 NNS	B-NP
that  	that  	 WDT	O
mimics  	mimics  	 VBZ	O
postconditioning  	postconditioning  	 JJ	B-NP
effects  	effects  	 NNS	I-NP
( 	( 	 -LRB-	O
e.g.  	e.g.  	 NNP	O
with  	with  	 IN	O
cyclosporine 	cyclosporine 	 NN	B-NP
)  	)  	 -RRB-	O
in  	in  	 IN	O
a  	a  	 DT	O
randomised 	randomised 	 NN	O
,  	,  	 ,	O
multicenter  	multicenter  	 JJ	B-NP
clinical  	clinical  	 JJ	I-NP
trial  	trial  	 NN	I-NP
with  	with  	 IN	O
properly  	properly  	 RB	O
designed  	designed  	 VBN	B-NP
endpoint 	endpoint 	 NN	I-NP
.  	.  	 .	O
To  	To  	 TO	O
date 	date 	 NN	O
,  	,  	 ,	O
most  	most  	 RBS	O
clinically  	clinically  	 RB	O
tested  	tested  	 VBN	B-NP
agents  	agents  	 NNS	I-NP
that  	that  	 IN	O
induced  	induced  	 JJ	O
endogenous  	endogenous  	 NNS	B-NP
cardioprotection  	cardioprotection  	 VBP	O
such  	such  	 JJ	O
as  	as  	 IN	O
adenosine 	adenosine 	 NN	B-NP
,  	,  	 ,	O
erythropoietin 	erythropoietin 	 NN	B-NP
,  	,  	 ,	O
protein  	protein  	 FW	B-NP
kinase  	kinase  	 FW	I-NP
C-δ  	C-δ  	 FW	I-NP
inhibitor 	inhibitor 	 FW	I-NP
,  	,  	 ,	O
atrial  	atrial  	 FW	B-NP
natriuretic  	natriuretic  	 FW	I-NP
peptide 	peptide 	 FW	I-NP
,  	,  	 ,	O
atorvastatin  	atorvastatin  	 NN	B-NP
and  	and  	 CC	O
nicorandil  	nicorandil  	 NNS	B-NP
were  	were  	 VBD	O
failed  	failed  	 VBN	O
to  	to  	 TO	O
reduce  	reduce  	 VB	O
infarct  	infarct  	 JJ	B-NP
size 	size 	 NN	I-NP
.  	.  	 .	O
Time  	Time  	 NN	O
will  	will  	 MD	O
tell  	tell  	 VB	O
whether  	whether  	 IN	O
postconditioning  	postconditioning  	 NN	B-NP
and  	and  	 CC	O
therapy  	therapy  	 NN	O
that  	that  	 IN	O
it  	it  	 PRP	O
mimics  	mimics  	 VBZ	O
meet  	meet  	 VB	O
expectation  	expectation  	 NN	O
and  	and  	 CC	O
find  	find  	 VB	O
place  	place  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
recommendations  	recommendations  	 NNS	B-NP
concerning  	concerning  	 VBG	I-NP
management  	management  	 NN	I-NP
of  	of  	 IN	O
acute  	acute  	 JJ	O
myocardial  	myocardial  	 JJ	B-NP
infarction 	infarction 	 NN	I-NP
.  	.  	 .	O
Kardiol  	Kardiol  	 NNP	O
Pol  	Pol  	 NNP	O
2011 	2011 	 CD	O
;  	;  	 :	O
69 	69 	 CD	O
,  	,  	 ,	O
supl 	supl 	 NN	B-NP
.  	.  	 .	O
III 	III 	 NNP	O
:  	:  	 :	O
67-74 	67-74 	 CD	O
.  	.  	 .	O
